Identification of PEG10 and TSG101 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma

Pathology and Oncology Research

Volumn 17, Issue 4, 2011, Pages 859-866

  Liu, Dong Cai ^a   Yang, Zhu Lin ^b   Jiang, Song ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Chronic cholecystitis; Gallbladder cancer; Gallbladder polyp; PEG10; TSG101

Indexed keywords

BIOLOGICAL MARKER; PEG10 PROTEIN; TRANSCRIPTION FACTOR; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GALLBLADDER CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADENOCARCINOMA; ADENOMATOUS POLYPS; ADULT; AGED; CELL DIFFERENTIATION; CHOLECYSTITIS; DISEASE PROGRESSION; DNA-BINDING PROTEINS; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; EPITHELIUM; FEMALE; GALLBLADDER; GALLBLADDER NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; PROGNOSIS; PROTEINS; REGRESSION ANALYSIS; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855457435     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-011-9394-7     Document Type: Article

References (34)

1. Ono R, Kobayashi S, Wagatsuma H et al (2001) A retrotransposonderived gene, PEG10, is a novel imprinted gene located on human chromosome 7q21. Genomics 73:232-237 (Pubitemid 32411360)
2. Okabe H, Satoh S, Furukawa Y et al (2003) Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. Cancer Res 63:3043-3048 (Pubitemid 36735848)
3. Kainz B, Shehata M, Bilban M et al (2007) Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia. Int J Cancer 121:1984-1993 (Pubitemid 47463161)
4. Tsuji K, Yasui K, Gen Y et al (2010) PEG10 is a probable target for the amplification at 7q21 detected in hepatocellular carcinoma. Cancer Genet Cytogenet 198:118-125
5. Chunsong H, Yuling H, Li Wet al (2006) CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23 + CD5+ B cells. J Immunol 177:6713-6722 (Pubitemid 44715035)
6. Li CM, Margolin AA, Salas M et al (2006) PEG10 is a c-MYC target gene in cancer cells. Cancer Res 66:665-672 (Pubitemid 43165928)
7. Ip WK, Lai PB, Wong NL et al (2007) Identification of PEG10 as a progression related biomarker for hepatocellular carcinoma. Cancer Lett 250:284-91 (Pubitemid 46529449)
8. Jie X, Lang C, Jian Q et al (2007) Androgen activates PEG10 to promote carcinogenesis in hepatic cancer cells. Oncogene 26:5741-5751 (Pubitemid 47312814)
9. Lux A, Beil C, Majety M et al (2005) Human retroviral gag- and gag-pol-like proteins interact with the transforming growth factorbeta receptor activin receptor-like kinase 1. J Biol Chem 280:8482-8493 (Pubitemid 40349753)
10. Ono R, Nakamura K, Inoue K et al (2006) Deletion of Peg10, an imprinted gene acquired from a retrotransposon, causes early embryonic lethality. Nat Genet 38:101-106 (Pubitemid 43011889)
11. Liu RT, Huang CC, You HL et al (2002) Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas. Oncogene 21:4830-4837
12. Young TW, Rosen DG, Mei FC et al (2007) Up-regulation of tumor susceptibility gene 101 conveys poor prognosis through suppression of p21 expression in ovarian cancer. Clin Cancer Res 13:3848-3854 (Pubitemid 47037590)
13. Koon N, Schneider-Stock R, Sarlomo-Rikala M et al (2004) Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 53:235-240 (Pubitemid 38125511)
14. Ma XR, Edmund Sim UH, Pauline B et al (2008) Overexpression of WNT2 and TSG101 genes in colorectal carcinoma. Trop Biomed 25:46-57
15. Li L, Liao J, Ruland J et al (2001) A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. Proc Natl Acad Sci USA 98:1619-1624 (Pubitemid 32165548)
16. Li L, Cohen SN (1996) Tsg101: A novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 85:319-329 (Pubitemid 26160704)
17. Zhu G, Gilchrist R, Borley N et al (2004) Reduction of TSG101 protein has a negative impact on tumor cell growth. Int J Cancer 109:541-547 (Pubitemid 38339644)
18. Bashirova AA, Bleiber G, Qi Y et al (2006) Consistent effects of TSG101 genetic variability on multiple outcomes of exposure to human immunodeficiency virus type 1. J Virol 80:6757-6763 (Pubitemid 44025175)
19. Goldin RD, Roa JC (2009) Gallbladder cancer: A morphological and molecular update. Histopathology 55:218-229
20. Gatto M, Bragazzi MC, Semeraro R et al (2010) Cholangiocarcinoma: Update and future perspectives. Dig Liver Dis 42:253-260
21. Jayaraman S, Jarnagin WR (2010) Management of gallbladder cancer. Gastroenterol Clin North Am 39:331-342
22. Maurya SK, Tewari M, Mishra RR (2010) Genetic abberations in gallbladder cancer. Surg Oncol Sep 28. [Epub ahead of print]
23. Sanada Y, Yoshida K, Ohara M, Tsutani Y (2007) Expression of orotate phosphoribosyltransferase (OPRT) in hepatobiliary and pancreatic carcinoma. Pathol Oncol Res 13:105-113 (Pubitemid 47204732)
24. Chang HJ, Yoo BC, Kim SW, Lee BL, Kim WH (2007) Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. Pathol Oncol Res 13:326-335 (Pubitemid 351287314)
25. Németh Z, Szász AM, Somorácz A, Tátrai P, Németh J et al (2009) Zonula Occludens-1, Occludin, and E-cadherin Protein Expression in Biliary Tract cancers. Pathol Oncol Res 15:533-539
26. Li Q, Yang Z (2009) Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations. J Exp and Clin Cancer Res 28:65-72
27. Li Q, Yang Z, Liu J, et al (2010). Expression of CDx2 and Hepatocyte antigen in benign and malignant lesions of gallbladder and its correlation with histopathologic typr and clinical outcome. Pathol Oncol Res Dec 28. 2010 [Epub ahead of print]
28. Malik IA (2004) Gallbladder cancer: Current status. Expert Opin Pharmacother 5:1271-1277 (Pubitemid 38885788)
29. Tucek S, Tomasek J, Halámkova J (2010) Bile duct malignancies. Klin Onkol 23:231-241
30. Zhao Y, You H, Liu F et al (2002) Differentially expressed gene profiles between multidrug resistant gastric adenocarcinoma cells and their parental cells. Cancer Lett 185:211-218
31. Shen H, Pan Y, Han Z et al (2004) Reversal of multidrug resistance of gastric cancer cells by downregulation of TSG101 with TSG101siRNA. Cancer Biol Ther 3:561-565 (Pubitemid 41351129)
32. Lee CT, Park KH, Yanagisawa K et al (2004) Combination therapy with conditionally replicating adenovirus and replication defective adenovirus. Cancer Res 64:6660-6665 (Pubitemid 39297927)
33. Lee CT, Lee YJ, Kwon SY et al (2006) In vivo imaging of adenovirus transduction and enhanced therapeutic efficacy of combination therapy with conditionally replicating adenovirus and adenovirus-p27. Cancer Res 66:372-377
34. Huang Q, Zhang X, Wang H et al (2004) A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin Cancer Res 10:1439-1445 (Pubitemid 38365239)